TrialEuropean heart journal2022

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.

Jean-Claude Tardif et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.